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Abstract 
BACKGROUND: There is evidence that both high and low frequency rTMS 
may have therapeutic effects on motor performance of Parkinson’s disease. 
OBJECTIVE: The aim of the study was to conduct the first direct comparison of 
the two approaches. 
METHODS: 52 PD patients were randomly classiﬁed into two groups. The ﬁrst 
group received 20Hz and the 2nd group received 1Hz rTMS with a total of 2000 
pulses over M1of each hemisphere for ten days.  Effects were assessed with 
the Unified Parkinson’s Disease Rating Scale part III (UPDRS), Instrumental 
Activity of Daily Living (IADL), and a self-assessment score (SA) before, after 
the last session, and one month later.  Cortical excitability was measured before 
and after the end of sessions. RESULTS: There was a significant improvement 
on all rating scales after either 1 Hz or 20 Hz rTMS, although but the effect was 
greaterpersisted for longer at after 20 Hz (treatment X time interaction for 
UPDRS  and IADL (P = 0.075 and 0.04 respectively). Neither treatment affected 
motor thresholds, but 20 Hz rTMS increased MEP amplitude and the duration 
of transcallosal inhibition. In an exploratory analysis, Eeach group was 
subdivided into akinetic-rigid and tremor dominant subgroups and the effects of 
1 Hz and 20 Hz treatment recalculated. There is was weak evidence that 
patients with an akinetic-rigid presentation may respond better than those with 
predominant tremor. 
CONCLUSION: Both 20 Hz and 1 Hz rTMS improve motor function in PD, but 
20 Hz rTMS is more effective and patients with an akinetic-rigid respond better 
than predominant tremor. 
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Introduction 
The therapeutic usefulness of various forms of non-invasive forms of brain 
stimulation has been examined in many studies in Parkinson's disease (PD), 
and has been the subject of a number of recent reviews and meta-analyses [1-
4]. But because of the variation in protocols (e.g. repetitive transcranial 
magnetic stimulation (rTMS) or transcranial direct current stimulation (TDCS), 
stimulation parameters (e.g. anodal or cathodal TDCS; high or low frequency 
rTMS), as well as the targeted cortical sites (e.g. motor cortex (M1), 
supplementary motor area, dorsolateral prefrontal cortex) it is very difficult to 
come to a clear conclusion about efficacy. 
Zanjani et al [5] recently conducted a meta-analysis of the effects of one of the 
commonest protocols and sites of therapeutic stimulation, rTMS on M1. Their 
analysis concentrated on studies that provided longer-term follow-up data (1 
month) as well as assessments of activity of daily living since they regarded 
both items as essential measures of clinical outcome. The conclusion was that 
the evidence was suggestive of a small positive effect on clinical outcome. 
However, they pointed out that in order to have sufficient data to conduct the 
analysis they had combined outcomes from trials using both low (usually 1 Hz) 
and high (usually 20 Hz) frequency rTMS. This may have increased the 
variation in outcome since there is evidence from studies in healthy individuals 
that these frequencies may have different effects on M1. Indeed, in an early 
study we [6] had observed that treatment with 25 Hz rTMS was superior to 10 
Hz rTMS, consistent with the idea that the effectiveness of rTMS to motor cortex 
may depend on the stimulus frequency. Zanjani et al [5] also concluded that in 
addition to providing overall motor outcomes via UPDRS III scores, further 
studies should also establish whether rTMS improves specific motor symptoms 
of PD, since there is some evidence that different symptoms may respond 
better than others. 
Here we address two of the questions posed by Zanjani et al [5]. First, we 
conducted a clinical trial to compare simply the effect of “standard” versions of 
high and low frequency rTMS: 1 Hz v 20 Hz with no sham group as several 
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other papers have reported positive effects of rTMS at various frequencies 
(versus sham) (i.e assuming the previous reports were correct).  
Second, we performed an exploratory  subsidiary analysis to examine whether 
rTMS had different effects on patients with primarily akinetic-rigid versus 
tremulous PD. 
 
 METHODS 
 PATIENTS  
62 consecutive patients (40 males, 22 females) who fulfilled the UK Parkinson’s 
Disease Brain Bank criteria for idiopathic PD [7] with ages between 50-70 years 
were recruited from those who attended the Department of Neurology, Aswan 
University Hospital, Egypt, from December 2016 to October 2017. Patients 
were divided into two subgroups, tremor-dominant and akinetic-rigid, on the 
basis of individual items of the UPDRS III scale as described by Lewis et al [8]. 
A tremor score was derived from the sum of UPDRS III items 20 (tremor at rest) 
and 21 (action or postural tremor of hands) divided by 7 [the number of single 
sub items (for each body region if separated) included]. A non-tremor score was 
derived from the sum of UPDRS III items 18 (speech), 19 (facial expression), 
22 (rigidity), 27 (arising from chair), 28 (posture), 29 (gait), 30 (postural 
stability), and 31 (body bradykinesia and hypokinesia) divided by 12 (the 
number of single sub items (for each body region (if separated) included). The 
patient was classified as tremor-dominant if the tremor score was at least twice 
the non-tremor score. Conversely, the patient was classified as akinetic-rigid 
type if the non-tremor score was at least twice the tremor score. The remaining 
patients, in whom the tremor and non-tremor score differed by less than a factor 
2, were classified as mixed type and were excluded.  
Out of 62 patients 12 patients were excluded: 6 patients had mixed type of PD, 
2 patients had a history of seizures, 2 patients had a history of cerebrovascular 
stroke. The remaining 52 patients participated in the clinical trial. All patients 
were receiving medication that was maintained constant for the duration of the 
trial. All participants or their caregivers gave informed consent before 
participation in the test and after full explanation of the study protocol. The local 
ethical committee of Aswan University Hospital approved the study protocol. 
 Experimental setup and design 
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All evaluations were performed by a clinician who was unaware of the treatment 
group. Patients were assessed clinically with part III of the Unified Parkinson’s 
Disease Rating Scale (UPDRS III) [9], and the instrumental activities of daily 
living (IADL) scale [10]. In addition we employed a self-assessment scale (SA) 
[11] as follows. Each patient was requested to evaluate the following nine 
parameters in a questionnaire: total body mobility, hand agility, walking, arising 
from chair, tremors, mood, concentration, sleep, and dreaming. Each of these 
were scored 1 (best), 2 (no change), or 3 (worst), and the patients were asked 
to judge the past 24 hours.  
 Electrophysiological assessments were performed using transcranial 
magnetic stimulation (TMS). Patients were seated comfortably in a reclining 
chair; biphasic rTMS pulses were delivered through a “figure 8” coil (outer 
diameter of each wing, 7 cm; maximum field strength, 1.9 Tesla) attached to a 
Magstim stimulator. Details of the methodology are given in Khedr et al [12]. In 
brief, we measured resting (rMT) and active (aMT) motor threshold, MEP 
amplitude at 130% rMT and duration of the ipsilateral silent period of the first 
dorsal interosseous muscle (FDI) using single TMS pulses with the coil held so 
as to induce currents approximately perpendicular to the line of the central 
sulcus.  
 Repetitive Transcranial Magnetic Stimulation (rTMS) 
The 52 patients were randomly assigned into two equal groups. One group 
received 2000 pulses of 20 Hz rTMS (delivered in trains of 5s with 25 s between 
trains) over the hand area of each motor cortex at 90% of RMT for each 
hemisphere (5 min between hemispheres). The other group received bilateral 
stimulation at 1 Hz rTMS (each hemisphere received two trains, separated by 
30s, of 1000 stimuli at 100% RMT). 
 Follow up of the patients 
 We followed up the patients clinically after the end of the 10th session and one 
month later using the same scales the same clinical rating scales (UPDRS part 
III, IDLA, and SA), as primary outcome. Cortical excitability was only measured 
after the end of the 10 treatment sessions as a secondary outcome. 
 Statistical analysis 
All data were analyzed with the aid of the SPSS ver.16. The results were 
expressed as mean ± SD. Since the distribution of the data did not differ 
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statistically from normality, statistical analysis of the scores in each test was 
performed with repeated measures analysis of variance (ANOVA) with TIME, 
as the within-subject factor, and treatment condition (20Hz, and 1Hz rTMS) as 
the between subject measure. Greenhouse–Geisser degree of freedom 
corrections were applied to correct for the non-sphericity of the data. P<0.05 
was considered significant for all statistical analysis. 
 
Results 
 
Clinical characteristics are summarised in Table 1. There were no significant 
differences between groups as regards age, sex, duration of illness, total score 
of UPDRS III, IADL, and SA scale. There was also no difference in the 
proportion of the predominant type of Parkinson’s disease (Akinetic-rigid/ 
tremor 16/10 versus 17/9 respectively). 
Patients were assessed clinically off medication at baseline (the day before the 
first rTMS session), the day after the last session, and then 1 month later. 
Physiological assessments were performed only at baseline and after the last 
treatment session.  
 
Effect on clinical scores (see Fig 2) 
Total group analysis (see Table 2A) 
 One way repeated measures ANOVA (pre, post treatment and one month 
later) showed a significant effect of time on all rating scales (UPDRS III, IADL, 
self-assessment) in both 1 Hz and 20 Hz treatment groups. Two-way repeated 
measures ANOVAs on the scores for each rating scale, with treatment 
CONDITION (1Hz and 20Hz) and TIME (baseline, post treatment, one month 
later) as main factors revealed a borderline significant interaction effect for 
UPDRS III (P = 0.075), and IADL scores (P = 0.04): 20 Hz rTMS was more 
effective than 1Hz rTMS. There was no significant interaction for self-
assessment scores. Finally, paired t-tests showed that at 1 month, scores on 
both the UPDRS III and IADL were significantly improved compared to baseline 
in the 20 Hz group (P< 0.01 in both cases), but not in the 1 Hz group. 
 
 Subgroup analysis (akinetic-rigid versus tremor-dominant groups) 
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In this exploratory analysis we investigated the possibility that akinetic-rigid 
patients might respond differently to tremor-dominant patients to the two 
frequencies of rTMS. An unintended limitationconsequence of the 
randomisation procedure was that the UPDRS III scores in both the akinetic-
rigid and the tremor-dominant groups differed between the 1 Hz and 25 Hz 
treatment protocols (see discussion). 
 
20 Hz rTMS (see Table 2B): one way ANOVA repeated measures analysis (pre, 
post session and one month later) showed a significant effect of time on all 
rating scales (UPDR, IADL, self-assessment) in the akinetic-rigid group, while  
significant improvement was only seen in UPDRS III and self-assessment 
scores for tremor-dominant patients. Two-way repeated measures ANOVAs on 
the scores for each rating scale, with condition (akinetic-rigid versus tremor) 
and time (baseline, post treatment, one month later) as main factors revealed 
a significant interaction only for UPDRS III (P = 0.013). This was due to the fact 
that high frequency rTMS was more effective in patients with akinetic-rigid than 
tremor-dominant PD. (Table 3). Post hoc paired t-tests showed that the UPDRS 
III score in the akinetic-rigid group was maintained at 1 month follow-up (P = 
0.01) but not in the tremor-dominant group. 
 
1 Hz rTMS (see Table 2C): There were no significant effects of treatment on 
the UPRDRS scores. However, one way repeated measures ANOVA (pre, post 
session and one month later) showed a significant effect of time on IADL in both 
akinetic-rigid and tremor-dominant groups and on self-assessment scores in 
the tremor-dominant group. Two-way repeated measures ANOVAs on the 
scores for each rating scale, with condition (akinetic-rigid versus tremor-
dominant) and time (baseline, post treatment, one month later) as main factors 
revealed a significant interactions for IADL, with larger effects on the tremor-
dominant group. The effects at one month were not different to baseline for 
either group in any of the scores. The conclusion is that 1 Hz rTMS did not have 
persisting effects on symptoms in either group of patients. 
 
Effects on cortical excitability (see Fig 3) 
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Given the differences in baseline scores, this analysis was only performed on 
the total group data. Neither frequency of rTMS had any effect on motor 
thresholds. However, 20 Hz rTMS increased MEP amplitude at 130% RMT and 
prolonged the duration of TCI, whereas there was no effect after 1 Hz rTMS. 
(See Table 3 for numerical data and statistical details.) 
 
Discussion 
The present study is the first to compare directly the effects of 10 consecutive 
day’s treatment with 1 Hz and 20 Hz rTMS over M1 in patients with Parkinson’s 
disease. Although both treatments transiently improved UPDRS III scores, 
there was a borderline tendency for a greater effect after 20 Hz. In addition, 
post hoc tests showed that only the group receiving 20 Hz rTMS maintained a 
significant effect at 1 month. 
 
Because of the evidence that there may be different clinical subtypes of patients 
with Parkinson’s disease who may potentially respond differently to treatment, 
we also conducted a subanalysis of the data by examining separately the 
effects on patients with an akinetic-rigid versus a tremor-dominant form of the 
condition. However, randomization resulted in different baseline UPDRS III 
scores in both the akinetic-rigid and tremor-dominant groups: the akinetic-rigid 
scores were higher at baseline than tremor-dominant scores in those treated 
with 20 Hz, whereas the opposite was true for treatment with 1 Hz. It is thus 
difficult to make a definitive conclusion about possible differential effects on 
clinical subtypes. Nevertheless, the data suggested that akinetic-rigid patients 
benefit from 20 Hz treatment whereas there was no significant effect on the 
tremor-dominant form. Treatment with 1 Hz rTMS had no significant effect on 
either group. Finally the effects of treatment on electrophysiological measures 
were consistent with the clinical effects and showed that MEP amplitude 
increased and cortical silent period duration decreased only after 20 Hz rTMS. 
Our conclusion is that 20 Hz rTMS over M1 may be superior to 1 Hz rTMS, 
particularly in patients with predominantly akinetic-rigid symptoms. 
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Khedr et al, [13] had measured the serum dopamine concentration before and 
after six sessions of 25 Hz rTMS over motor cortex in 20 PD patients. They 
found that the improvement in UPDRS was paralleled by an increase in plasma 
levels of dopamine. Although they only measured dopamine in plasma, it seems 
likely that the changes observed reﬂected changes in cerebral dopamine levels. 
Our results support the meta-analysis that confirmed the superiority of high-
frequency stimulation over low-frequency stimulation [1]. 
The results of the present study are in contrast with the results of Mally et al 
[14]. In their study, sixty-six patients with PD were included and randomly 
divided into three groups. The eﬀects of 1 Hz, 5 Hz and 5 + 1 Hz frequency at 
low intensity over each DLPFC and the brain stem for 7 days were compared. 
Patients were followed for six months. They found that only 1Hz had an eﬀect 
on motor scores. Five Hertz and 5 + 1 Hz did not cause improvement. However, 
this was an open study trial and used a lower intensity of rTMS than in the 
present study (25% of maximum output). 
 
Although the UPDRS III was our primary outcome measure, we also evaluated 
patients with the IADL and SA scores. The IADL scores followed a similar 
pattern to the UPDRS III scores in the total group analysis, and confirmed that 
rTMS was an effective form of treatment that improved overall activity as well 
as specific motor signs. In the subanalysis there was a larger effect on the 
tremor-dominant group after 1 Hz rTMS. Siebner et al [15] also noted an effect 
on tremor after 5 Hz rTMS which may indicate that lower frequencies of rTMS 
could be more effective for symptoms of tremor although more data is needed 
to substantiate this point. Self-assessment scores did not correlate well with the 
objective UPDRS III and IADL scores. Patients tended to respond that both 
forms of treatment were beneficial, even when the other scores indicated little 
overall change. 
 
It was interesting to note that in the total group analysis, the immediate effects 
of both 1 Hz and 20 Hz rTMS were similar, but that the effect at 1 month follow-
up was only maintained after 20 Hz rTMS. Strafella et al [16] showed that a 
single session of 10 Hz rTMS to M1 caused dopamine release in the striatum. 
Although Strafella et al [16] did not explore the effects of different frequencies 
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of rTMS, it could be that both frequencies of stimulation used here lead to 
immediate increases in dopamine release and that this is responsible for the 
initial effect. The implication would be that the longer term benefit at one month 
was due to a different mechanism, presumably involving some more permanent 
changes in neural network activity. 
 
Although the major objective of the study was to examine the clinical 
effectiveness of rTMS therapy, we also included outcome measures of motor 
cortical excitability. These are useful because they provide an independent and 
objective measure of the response to rTMS that is not compromised by 
behavior. Previous work in healthy individuals has suggested that low 
frequencies (such as 1 Hz) of rTMS are likely to reduce cortical excitability by 
effects on synaptic plasticity whereas higher frequencies do the opposite. This 
was true here: 20 Hz rTMS increased excitability as measured by the larger 
response to single TMS pulses, while there was a tendency for excitability to 
be reduced after 1 Hz rTMS. We conclude that rTMS did have an objective 
effect on the cortical motor system in our participants. Thresholds were 
unchanged as expected since these depend on the properties of ion channels 
in the neural membrane which are unaffected by rTMS. The combination of 
unchanged threshold with increased MEP amplitudes is compatible with the 
idea that the input-output relationship of cortical excitability is steeper after 20 
Hz rTMS, which may be advantageous for movement initiation There was also 
a significant increase in the duration of TCI after 20 Hz rTMS, but the 
significance of this is unclear since the amplitude of the MEP also increased 
and this in itself could affect TCI.  
As noted in many previous studies, there may be no direct relationship between 
these physiological measures and the clinical outcome. Importantly, though, 20 
Hz rTMS had a more significant effect on excitability measures than 1 Hz rTMS, 
which did reflect our overall clinical conclusion. 
 
Conclusion and recommendation: 
20 Hz rTMS over M1 appears to be more effective than 1 Hz rTMS particularly 
at longer follow-up. Our exploratory analysis suggested that the effects of 
rTMS might be slightly better iin patients with a predominantly akinetic-rigid 
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clinical presentation. However, the evidence is weak and studies with larger 
(i.e. >26 per treatment group) numbers of patients are need to confirm this 
work.  
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Figure legends: 
 
Figure 1. 
Consort diagram indicating recruitment and treatment staging. 
 
Figure 2. 
Time course of changes in UPDRS, IADL and self-assement (SA) scores from 
before, immediately after 10 day’s rTMS and 1 month later. The top row 
summarises data from the total group of patients, and compares the effects of 
treatment with 1 Hz v 20 Hz rTMS. The middle and bottom rows compare the 
effects of 20 Hz rTMS (middle row) and 1 Hz rTMS (bottom row) on the 
patient subgroups (akinetic-rigid versus tremor-dominant symptoms). Points 
are the mean ± SD. Statistical details are given in Table 2. 
 
Figure 3. 
The effect of 20 Hz and 1 Hz rTMS on the duration of transcallosal inhibition 
(left panel) and MEP amplitude (right panel) following a TMS pulse of 130% 
rMT 
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Table 1: Demographic, clinical and staging data at baseline assessment  
 
Variable 
High frequency rTMS Group (26 
patients). Mean ± SD 
Low frequency rTMS Group (26 
patients). Mean ± SD 
P value 
T test 
Patients Age (years) 59.58 ± 11.28 55.88 ± 13.84 0.279 
Age at Onset (years) 54.98 ± 12.92 51.00 ± 13.68 0.286 
Duration of Illness (years) 4.60 ± 3.64 4.85 ± 3.39 0.799 
Total Score of UPDRS III 45.54 ± 20.01 46.46 ± 22.37 0.876 
 IADL 18.42 ± 6.86 19.31 ± 6.60 0.638 
SA 16.38 ± 4.62 16.27 ± 5.20 0.933 
 
UPDRS III; Unified Parkinson’s Disease Rating Scale  IADL ; instrumental activities of daily 
living, SA; self-assessment scale.  
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Table 2A: Effect of 20Hz versus1Hz rTMS in total group 
 
 
 
Table 2B: Effect of 20Hz rTMS in relation to the dominant type of PD  
Measure dominant type of PD 
(number of patients) 
Pre- 
Mean ± SD 
Post 
Mean ± SD 
1-month post 
Mean ± SD 
ONE way ANOVA 
(‘time for each group’) 
Two way ANOVA 
(‘time X group’) 
UPDRS III Akinetic rigid (16) 
Tremors (10) 
51.9 ± 19.80 
34.6 ± 16.1 
35.62 ± 14.94 
29.2 ± 12.02 
37.19 ± 13.64 
30.30 ± 11.68 
df = 1,1, F = 25.2, P=0.0001 
df = 1,2, F = 6.9, P=0.02 
df = 1.1, 27; F = 6.8 
P = 0.013 
IADL Akinetic rigid (16) 
Tremors (10) 
16.19 ± 6.74 
22.00 ± 5.56 
19.75 ± 5.89 
23.90 ± 4.45 
19.44 ± 5.78 
23.51 ± 4.38 
df = 1.2, F = 12.3, P= 0.002 
df = 1.5, F = 3.4, P= 0.07 
df = 1.2, F = 1,3 
P= 0.27 
SA Akinetic rigid (16) 
Tremors (10) 
17.81 ± 4.36 
14.10 ± 4.28 
14.56 ± 4.29 
12.00 + 2.16 
14.93 ± 4.40 
12.00± 2.16 
df = 1.2, F = 10.1, P= 0.003 
df = 1.1, F = 8.1, P = 0.01 
df = 1.1, F = 0.20 
P = 0.69 
 
 
 
Table 2C: Effect of 1Hz rTMS in relation to the dominant type of PD 
 
Measure dominant type of PD 
(number of patients) 
Pre- 
Mean ± SD 
Post 
Mean ± SD 
1-month post 
Mean ± SD 
ONE way ANOVA 
(‘time for each group’) 
Two way ANOVA 
(‘time X group’) 
UPDRS III Akinetic rigid (17) 
Tremors (9) 
38.68 ± 16.80 
67.57 ± 22.94 
31.26 ± 20.23 
56.86 ± 23.12 
35. ± 22.75 
61.43 ± 25.13 
df = 1,1, F = 3.7, P=0.06 
df = 1,1, F = 4.4, P=0.06 
df = 1.2, 28; F = 
0.66, P = 0.44 
IADL Akinetic rigid (17) 
Tremors (9) 
21.11 ± 5.76 
14.43 ± 6.63 
23.58 ± 5.57 
16.43 ± 6.05 
21.84 ± 6.35 
14.29 ± 6.75 
df = 1.8, F = 5.3, P= 0.013 
df = 1.4, F = 5.2, P= 0.03 
df = 1.4, F = 06.36 
P = 0.009 
   SA Akinetic rigid (17) 
Tremors (9) 
14.79 ± 4.54 
20.29 ± 5.02 
12.47 ± 4.98 
18.29 ± 5.79 
13.16 ± 4.79 
18.29 ± 5.79 
df = 1.1, F = 15.5, P= 0.001 
df = 1.3, F = 4.3, P = 0.057 
df = 1.4 , F = 0.1 
P = 0.82 
 
UPDRS III; Unified Parkinson’s Disease Rating Scale  IADL ; instrumental activities of daily 
living, SA; self-assessment scale.  
  
Measure Group (number of patients)  Pre- 
Mean ± SD 
Post 
Mean ± SD 
1-month post 
Mean ± SD 
ONE way ANOVA 
(‘time for each group’) 
Two way ANOVA 
(‘time X group’) 
UPDRS III 20Hz rTMS Group (26) 
1Hz rTMS Group (26) 
45.27 ± 20.01 
46.46 ± 22.37 
33.15 ± 14.05 
38.15 ± 23.60 
34.54 ± 13.02 
42.62 ± 25.69 
df = 1,1, F = 28.3, P=0.0001 
df = 1.2, F = 8.1, P = 0.006 
df=1.1, 57; F=4.809 
P = 0.075 
IADL 20Hz rTMS Group (26) 
1Hz rTMS Group (26) 
18.42 ± 6.86 
19.31 ± 6.60 
21.35 ± 5.68 
21.65 ± 6.45 
21.00 ± 5.57 
19.81 ± 7.19 
df = 1.2, F = 14.9, P= 0.0001 
df = 1.8, F = 10.4, P = 0.001 
df = 1.6, 79; F = 3.5 
P = 0.044 
SA 20Hz rTMS Group (26) 
1Hz rTMS Group (26) 
16.38 ± 4.62 
16.27 ± 5.20 
13.58 ± 3.79 
14.04 ± 5.73 
13.81 ± 3.95 
14.54 ± 5.47 
df = 1.2, F = 17.1, P= 0.0001 
df = 1.3, F = 13.3., P =0.0001 
df = 1.4, F = 0.76 
P = 0.46 
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Table 3: Effect of rTMS on cortical excitability parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Group (number of patients)  Pre 
Mean ± SD 
Post 
Mean ± SD 
P-Value 
(Paired T-test) 
Repeated measure analysis  
(Two way ANOVA Time x group) 
RMT 20 Hz  rTMS Group (26) 
1 Hz rTMS Group (26) 
37.46 ± 7.16 
36.96 ± 4.08 
36.65 ± 8.44 
37.62 ± 5.89 
0.511 
0.552 
df = 1, F = 0.80, P = 0.37 
AMT 20Hz  rTMS Group (26) 
1Hz  rTMS Group (26) 
29.54 ± 6.33 
28.88 ± 4.48 
28.65 ± 7.14 
29.65 ± 5.37 
0.414 
0.434 
df = 1, F = 1.32, P = 0.25 
MEP (130% 
RMT) (mV) 
20HzrTMS Group (26) 
1Hz rTMS Group (26) 
1.20 ± 0.36 
1.00 ± 0.51 
1.47 ± 0.31 
0.81 ± 0.48 
0.0001 
0.087 
df = 1, F = 14.85, P = 0.0001 
TCI duration (ms) 20Hz rTMS Group (26) 
1Hz rTMS Group (26) 
32.46 ± 7.93 
40.74 ± 16.81 
36.27 ± 6.58 
38.18 ± 8.89 
0.005 
0.333 
df = 1, F = 4.88, P = 0.032 
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: flow chart 
 
 
  
10 patients were excluded 
6 patients have severe dementia 
2 patients had history of seizures 
2 patients refuse to participate 
 
 
 
 
52 patients were 
randomized 
Potential participants screened (n=62) 
Follow up visits 
sessions, and  th, post 10sessions-Pre
one month later 
 
20 Hz rTMS group 
26 patients completed 
the study 
1 Hz rTMS group 
 26 patients completed 
the study 
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Figure 2 
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